Intravascular Ultrasound Use in Peripheral Arterial and Deep Venous Interventions: Multidisciplinary Expert Opinion From SCAI/AVF/AVLS/SIR/SVM/SVS.

Percutaneous revascularization is the primary strategy for treating lower extremity venous and arterial disease. Angiography is limited by its ability to accurately size vessels, precisely determine the degree of stenosis and length of lesions, characterize lesion morphology, or correctly diagnose postintervention complications. These limitations are overcome with use of intravascular ultrasound (IVUS). IVUS has demonstrated the ability to improve outcomes following percutaneous coronary intervention, and there is increasing evidence to support its benefits in the setting of peripheral vascular intervention. At this stage in its evolution, there remains a need to standardize the use and approach to peripheral vascular IVUS imaging. This manuscript represents considerations and consensus perspectives that emerged from a roundtable discussion including 15 physicians with expertise in interventional cardiology, interventional radiology, and vascular surgery, representing 6 cardiovascular specialty societies, held on February 3, 2023. The roundtable's aims were to assess the current state of lower extremity revascularization, identify knowledge gaps and need for evidence, and determine how IVUS can improve care and outcomes for patients with peripheral arterial and deep venous pathology.

CT angiography in the evaluation of acute pulmonary embolus.

OBJECTIVE: The purpose of this study was to assess the appropriate use of CT angiography (CTA) in the diagnostic evaluation of acute pulmonary embolism (PE). MATERIALS AND METHODS: We reviewed a total of 575 CT angiograms obtained to evaluate for PE at a large level 1 trauma teaching hospital from January 2004 through March 2005. Various clinical settings were used for 267 inpatient (46%), 258 emergency department (45%), and 50 outpatient (9%) studies. We excluded CTA performed for other reasons, repeated CTA, and patient records with incomplete clinical data. On the basis of chart review in which the investigators were blinded to final diagnoses, pretest probability of PE according to the Wells criteria was retrospectively assigned to each patient. D-dimer values, when obtained, also were reviewed. The diagnosis of PE was based on final CTA reports. RESULTS: PE was diagnosed in 9.57% of 575 patients. Positivity rates by location were 32 (12%) of the 267 inpatients, 22 (8.5%) of the 258 emergency department patients, and one (2.0%) of the 50 outpatients. Three (< 1%) of the 575 patients had high probability of PE, even though 351 patients had gone directly to CTA. Of the other 572 patients, 158 (28%) had intermediate and 414 (72%) low probability of PE. In the high, intermediate, and low probability groups, two (67%), 24 (15%), and 29 (7%), respectively, of the patients had PE. A D-dimer assay was performed for 224 (39%) of the 575 patients. Thirty-nine (17%) of the 224 patients had normal results (< 0.5 microg/mL); 107 (48%), intermediate results (0.6-2.0 microg/mL); and 78 (35%), abnormal results (> 2.0 microg/mL). In the emergency department cohort, 151 (59%) of 258 patients underwent a D-dimer assay. Thirty-two (21%) of the 151 patients had normal results; 81 (54%), intermediate results; and 38 (25%), abnormal results. Only one patient with a normal D-dimer level and three patients with intermediate D-dimer levels had PE, the equivalent of 3% of each group. The number of CTA examinations ordered for patients with normal and intermediate D-dimer results was 146 (25% of the 575 total studies). Twenty-two (8%) of the 258 emergency department patients had PE, and clinical suspicion of PE was high for 11 (50%), intermediate for 10 (45%), and low for one (5%) of those patients. CONCLUSION: Our data showed suboptimal use of the Wells criteria and subjective overestimation of the probability of PE before ordering of CTA. Although a definitive acceptable PE positivity rate for CTA has not been established, the 10% yield represents overuse of CTA as a screening rather than a diagnostic examination.

Comparison of long-term outcomes of myomectomy and uterine artery embolization.

OBJECTIVE: To compare long-term outcomes of uterine artery embolization and abdominal myomectomy in patients with symptomatic uterine myomas. METHODS: At a single institution in an 18-month time, 59 patients had bilateral uterine artery embolization and 38 patients had abdominal myomectomy to treat symptomatic uterine myomas. We reviewed medical records and surveyed patients 3 or more years after their procedures to assess how many needed further surgical procedures in the intervening years, to what extent symptoms remained improved, and how satisfied the patients were with the long term results of the index procedure. RESULTS: Follow-up was available on 51 embolization and 30 myomectomy patients and ranged from 37 to 59 months. Patients who had embolization were older (44 versus 38 years, P <.001) and more likely to have had previous surgical procedures (P <.001) than those who had myomectomy. Taking into account the variable follow-up period, embolization patients were more likely to have had further invasive treatment for myomas (29% versus 3%) (P =.004). Among women not needing further surgery, overall symptoms improved in 92% (33/36) of embolization and 90% (26/29) of myomectomy patients (P =.78). Ninety-four percent (34/36) of embolization patients and 79% (23/29) of myomectomy patients were at least somewhat satisfied with their choice of procedure (P =.06). CONCLUSION: Women who had embolization were more likely than those who had myomectomy to need further invasive treatment (surgery or repeat embolization) in the 3-5 years after the index procedure. Among women who did not need such treatment, satisfaction and relief of symptoms were similar. Large, randomized trials are needed to more accurately compare these two procedures.

Basal ganglia: anatomy, pathology, and imaging characteristics.

Several cases of bilateral basal ganglia lesions seen in magnetic resonance imaging initiated a review of the anatomy, pathology, and differential diagnoses of this region. There are a variety of disease entities that present as symmetrical basal ganglia abnormalities. Although these findings may not indicate a specific diagnosis, knowledge of the characteristics of diseases that affect this area can limit the differential considerations. Clinical information is often essential for narrowing the possible pathology that can be found here. The purpose of this article is to review the anatomy of the basal ganglia, the pathologies, clinical histories, and imaging characteristics that can cause bilateral basal ganglia lesions.

Intense inflammatory reaction to heparin polymer coated intravascular Palmaz stents in porcine arteries compared to uncoated Palmaz stents.

The objective of this study was to evaluate the efficacy of heparin-polymer-coated intravascular stents in the reduction of vessel stenosis. Three types of coatings for Palmaz stents were tested: 1) heparin covalently bound to a polyethylene oxide (Hp-PEO) tether; 2) heparin copolymerized with ethylene vinyl acetate (Hp-Elvax) and 3) Elvax alone. Polymer-coated stents and uncoated controls were deployed in the external iliac arteries following endothelial injury in 18 swine. The animals were maintained on an atherogenic diet and examined by angiography at 6 and 12 weeks. The stented segments were then harvested for histopathologic analysis. Both types of heparin-coated stents resulted in increased luminal narrowing as compared to the contralateral uncoated stents. At 6 weeks, average luminal stenosis was 48% for Hp-PEO stents vs 35% for uncoated stents (p <0.05). At 12 weeks, average luminal stenosis was 36% for Hp-PEO stents vs 26% for uncoated stents (p = NS). For Hp-Elvax stents, the average stenosis was 58% vs 33% for uncoated controls (p < 0.05) at 6 weeks and 47% vs 19% for uncoated controls (p <0.05) at 12 weeks. There was no significant difference between Hp-Elvax stents and Elvax stents (p = NS). Increased luminal narrowing in coated stents was primarily secondary to a marked inflammatory response. Heparin-polyethylene oxide and heparin-ethylene vinyl acetate-coated stents resulted in increased luminal narrowing as compared with uncoated stents, due to a marked inflammatory response.